Grifols (NASDAQ:GRFS) Cut to "Buy" at Wall Street Zen

Wall Street Zen downgraded shares of Grifols (NASDAQ:GRFS - Free Report) from a strong-buy rating to a buy rating in a research note issued to investors on Sunday morning.

Separately, JPMorgan Chase & Co. increased their target price on shares of Grifols from $7.60 to $10.30 and gave the stock a "neutral" rating in a research report on Tuesday, June 17th.

Grifols Stock Up 1.1%

GRFS stock traded up $0.10 during trading hours on Friday, hitting $9.10. The company's stock had a trading volume of 160,046 shares, compared to its average volume of 1,124,304. The stock has a 50 day moving average price of $8.13 and a two-hundred day moving average price of $7.67. Grifols has a 12 month low of $6.19 and a 12 month high of $9.96. The company has a market capitalization of $6.25 billion, a PE ratio of 7.77, a price-to-earnings-growth ratio of 0.33 and a beta of 0.55. The company has a quick ratio of 0.97, a current ratio of 2.60 and a debt-to-equity ratio of 1.13.

Institutional Investors Weigh In On Grifols

A number of large investors have recently added to or reduced their stakes in the stock. Versant Capital Management Inc bought a new position in shares of Grifols in the first quarter valued at approximately $28,000. Tower Research Capital LLC TRC grew its stake in Grifols by 354.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock valued at $60,000 after buying an additional 6,335 shares during the last quarter. First Trust Advisors LP bought a new position in Grifols in the 4th quarter worth $75,000. Envestnet Portfolio Solutions Inc. bought a new stake in Grifols during the fourth quarter valued at about $77,000. Finally, Ballentine Partners LLC bought a new stake in Grifols during the first quarter valued at about $77,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.